Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer

Navid Sobhani, Anna Ianza, Alberto D'Angelo, Giandomenico Roviello, Fabiola Giudici, Marina Bortul, Fabrizio Zanconati, Cristina Bottin, Daniele Generali

Research output: Contribution to journalReview article

Abstract

Breast cancer (BC) is the most common malignancy and second only to lung cancer in terms of mortality in women. Despite the incredible progress made in this field, metastatic breast cancer has a poor prognosis. In an era of personalized medicine, there is an urgent need for better knowledge of the biology leading to the disease, which can lead to the design of increasingly accurate drugs against patients' specific molecular aberrations. Among one of the actionable targets is the fibroblast growth factor receptor (FGFR) pathway, triggered by specific ligands. The Fibroblast Growth Factor Receptors/Fibroblast Growth Factors (FGFRs/FGFs) axis offers interesting molecular targets to be pursued in clinical development. This mini-review will focus on the current knowledge of FGFR mutations, which lead to tumor formation and summarizes the state-of-the-art therapeutic strategies for targeted treatments against the FGFRs/FGFs axis in the context of BC.

Original languageEnglish
JournalCells
Volume7
Issue number7
DOIs
Publication statusPublished - Jul 15 2018

Fingerprint

Fibroblast Growth Factor Receptors
Breast Neoplasms
Fibroblast Growth Factors
Precision Medicine
Second Primary Neoplasms
Therapeutics
Aberrations
Medicine
Tumors
Lung Neoplasms
Ligands
Mutation
Mortality
Pharmaceutical Preparations
Neoplasms

Cite this

Sobhani, N., Ianza, A., D'Angelo, A., Roviello, G., Giudici, F., Bortul, M., ... Generali, D. (2018). Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer. Cells, 7(7). https://doi.org/10.3390/cells7070076

Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer. / Sobhani, Navid; Ianza, Anna; D'Angelo, Alberto; Roviello, Giandomenico; Giudici, Fabiola; Bortul, Marina; Zanconati, Fabrizio; Bottin, Cristina; Generali, Daniele.

In: Cells, Vol. 7, No. 7, 15.07.2018.

Research output: Contribution to journalReview article

Sobhani, N, Ianza, A, D'Angelo, A, Roviello, G, Giudici, F, Bortul, M, Zanconati, F, Bottin, C & Generali, D 2018, 'Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer', Cells, vol. 7, no. 7. https://doi.org/10.3390/cells7070076
Sobhani, Navid ; Ianza, Anna ; D'Angelo, Alberto ; Roviello, Giandomenico ; Giudici, Fabiola ; Bortul, Marina ; Zanconati, Fabrizio ; Bottin, Cristina ; Generali, Daniele. / Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer. In: Cells. 2018 ; Vol. 7, No. 7.
@article{2804457ec1ba4fe9ac8367dbc7ba12af,
title = "Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer",
abstract = "Breast cancer (BC) is the most common malignancy and second only to lung cancer in terms of mortality in women. Despite the incredible progress made in this field, metastatic breast cancer has a poor prognosis. In an era of personalized medicine, there is an urgent need for better knowledge of the biology leading to the disease, which can lead to the design of increasingly accurate drugs against patients' specific molecular aberrations. Among one of the actionable targets is the fibroblast growth factor receptor (FGFR) pathway, triggered by specific ligands. The Fibroblast Growth Factor Receptors/Fibroblast Growth Factors (FGFRs/FGFs) axis offers interesting molecular targets to be pursued in clinical development. This mini-review will focus on the current knowledge of FGFR mutations, which lead to tumor formation and summarizes the state-of-the-art therapeutic strategies for targeted treatments against the FGFRs/FGFs axis in the context of BC.",
author = "Navid Sobhani and Anna Ianza and Alberto D'Angelo and Giandomenico Roviello and Fabiola Giudici and Marina Bortul and Fabrizio Zanconati and Cristina Bottin and Daniele Generali",
year = "2018",
month = "7",
day = "15",
doi = "10.3390/cells7070076",
language = "English",
volume = "7",
journal = "Cells",
issn = "2073-4409",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "7",

}

TY - JOUR

T1 - Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer

AU - Sobhani, Navid

AU - Ianza, Anna

AU - D'Angelo, Alberto

AU - Roviello, Giandomenico

AU - Giudici, Fabiola

AU - Bortul, Marina

AU - Zanconati, Fabrizio

AU - Bottin, Cristina

AU - Generali, Daniele

PY - 2018/7/15

Y1 - 2018/7/15

N2 - Breast cancer (BC) is the most common malignancy and second only to lung cancer in terms of mortality in women. Despite the incredible progress made in this field, metastatic breast cancer has a poor prognosis. In an era of personalized medicine, there is an urgent need for better knowledge of the biology leading to the disease, which can lead to the design of increasingly accurate drugs against patients' specific molecular aberrations. Among one of the actionable targets is the fibroblast growth factor receptor (FGFR) pathway, triggered by specific ligands. The Fibroblast Growth Factor Receptors/Fibroblast Growth Factors (FGFRs/FGFs) axis offers interesting molecular targets to be pursued in clinical development. This mini-review will focus on the current knowledge of FGFR mutations, which lead to tumor formation and summarizes the state-of-the-art therapeutic strategies for targeted treatments against the FGFRs/FGFs axis in the context of BC.

AB - Breast cancer (BC) is the most common malignancy and second only to lung cancer in terms of mortality in women. Despite the incredible progress made in this field, metastatic breast cancer has a poor prognosis. In an era of personalized medicine, there is an urgent need for better knowledge of the biology leading to the disease, which can lead to the design of increasingly accurate drugs against patients' specific molecular aberrations. Among one of the actionable targets is the fibroblast growth factor receptor (FGFR) pathway, triggered by specific ligands. The Fibroblast Growth Factor Receptors/Fibroblast Growth Factors (FGFRs/FGFs) axis offers interesting molecular targets to be pursued in clinical development. This mini-review will focus on the current knowledge of FGFR mutations, which lead to tumor formation and summarizes the state-of-the-art therapeutic strategies for targeted treatments against the FGFRs/FGFs axis in the context of BC.

U2 - 10.3390/cells7070076

DO - 10.3390/cells7070076

M3 - Review article

C2 - 30011957

VL - 7

JO - Cells

JF - Cells

SN - 2073-4409

IS - 7

ER -